BCL2 and B-cell chronic lymphocytic leukemia: The orally bioavailable BCL-2 inhibitor VEN has proven effectiveness in chronic lymphocytic leukemia (CLL) and other hematological malignancies11,14–18, and has been implemented into regimens treating CLL patients33.